Save time and money with early immunogenicity assessment


All biotherapeutic proteins have the potential to elicit  an immune response when administered to humans. The patient’s immune response to a biotherapeutic protein is usually determined by measuring the levels of antibodies directed against the protein, known as anti-drug antibodies (ADA). The consequences of generating unwanted ADA may include partial or complete loss of drug efficacy, altered  pharmacokinetics/pharmacodynamics or, in some cases, cross reaction with endogenous proteins. In certain situations, these effects can even result in life-threatening reactions.

Our immunogenicity assessment services address the challenge of unwanted immune responses throughout the drug development cycle. By managing potential drug immunogenicity at the earliest possible stage, you can save time and money while creating a safer, more effective biotherapeutic protein for the market.

Our Epibase® suite of in silico immunoprofiling services and in vitro cellular  assays  predict  and compare the immunogenicity risk potential of the biotherapeutic protein. Our Applied Protein Services experts will work with you to customize your assessment strategy based on your therapeutic goal and timeline. Epibase® in silico and in vitro platforms provide the most comprehensive immunogenicity assessment package offered.

Customer quote: “Lonza’s Epibase® in silico immunogenicity assessment supported our antibody engineering which enabled us to evaluate the technology more appropriately. The assessment didn’t add significant time to our project and the Lonza team was very responsive and provided valuable input on our project” -Sysmex Corporation

Immunogenicity services for biotherapeutics


We offer in silico and in vitro assessment services to screen biotherapeutic and vaccine candidates for their immunogenicity potential. Our Epibase® tools help predict the immunogenicity of candidates thereby promoting knowledge-based decisions regarding candidate selection in the early discovery and development phases. The tools can also aid in the monitoring of immunogenicity during clinical phases.

technology
Epibase® in vitro screening for biotherapeutics
Our proprietary Epibase® in vitro platform evaluates the immunogenicity risk of biotherapeutic proteins by directly measuring the immune response induced by the protein in peripheral blood mononuclear cells (PBMCs).
technology
Epibase® in silico screening for biotherapeutics
Our proprietary Epibase® in silico platform is a patented T cell epitope screening tool for the identification of potential epitopes in a biotherapeutic protein.
The safety and efficacy of biological candidates are critical to their clinical success. Learn how we can help.

Download Presentation

Immunogenicity risk assessment: Using pre-clinical tools during lead selection and optimization.